文献速递青光眼

罗格列酮治疗可预防青光眼滤过手术兔模型术后纤维化

Rosiglitazone Treatment Prevents Postoperative Fibrosis in a Rabbit Model of Glaucoma Filtration Surgery.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

研究在甲基纤维素诱导慢性高眼压的新西兰白兔青光眼滤过手术模型中评估罗格列酮(RSG)的抗纤维化作用,并在人Tenon囊成纤维细胞(HTF)中探讨机制。RSG减轻术后眼压反跳、延长滤过泡存活并减轻结膜下纤维化,其作用与经beclin1/VPS34依赖途径增强自噬、抑制促纤维化基因表达相关。

要点

  • RSG减轻兔滤过手术后眼压反跳、延长滤过泡存活并减轻结膜下纤维化
  • RSG抑制TGF-β1诱导的Sp1、CTGF和α平滑肌肌动蛋白表达
  • RSG经beclin1/VPS34依赖机制增强HTF自噬,自噬增强与抑制促纤维化基因表达相关

核心结论

  • RSG通过促进局部成纤维细胞自噬、抑制促纤维化基因表达,预防青光眼滤过手术后的结膜下纤维化。
  • RSG是一种新型抗纤维化药物,有潜力提高青光眼滤过手术的成功率。

研究设计与样本

  • 在体实验采用经前房注射2%甲基纤维素建立慢性高眼压的成年雄性新西兰白兔,行青光眼滤过手术,术中分别予RSG、丝裂霉素C(MMC)或5-氟尿嘧啶(5-FU)处理。
  • 用Indiana滤过泡外观分级量表(IBAGS)评分评估滤过泡形态,用定量PCR、免疫印迹和/或组织化学分析检测促纤维化基因表达。
  • 体外实验在基于转化生长因子(TGF)-β1的纤维化细胞模型中进行,用荧光显微镜和透射电镜观察自噬体与自噬溶酶体形成,并检测自噬通路关键介质的表达。

主要发现

  • RSG改善兔小梁切除术后眼压反跳性升高、延长滤过泡存活并减轻结膜下纤维化。
  • RSG预处理抑制HTF中TGF-β1诱导的 specificity protein 1、结缔组织生长因子和α平滑肌肌动蛋白等促纤维化基因表达。
  • RSG经beclin1/VPS34依赖机制增强HTF中TGF-β1诱导的自噬,自噬增强与RSG抑制TGF-β1诱导的促纤维化基因表达相关。

临床怎么用

  • 作者认为RSG是一种新型抗纤维化药物,有潜力提高青光眼滤过手术的成功率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the potential antifibrotic effect of rosiglitazone (RSG), a peroxisome proliferator-activated receptor γ (PPARγ)-selective agonist, on subconjunctival fibrosis in a rabbit model of glaucoma filtration surgery (GFS) in vivo, and to investigate the underlying mechanisms in human Tenon's fibroblasts (HTFs) in vitro. METHODS: GFS were performed on adult male New Zealand white rabbits with chronic ocular hypertension previously established by injections of 2% methylcellulose into the anterior chamber. Rabbits were treated by RSG, mitomycin C (MMC) or 5-fluorouracil (5-FU) intraoperatively. The morphology of filtering blebs was evaluated by Indiana Bleb Appearance Grading Scale (IBAGS) scoring. Expression of profibrotic genes was determined by quantitative PCR, immunoblot, and/or histochemical analysis. In vitro studies were performed in a transforming growth factor (TGF)-β1-based cell model of fibrosis. Autophagy was evaluated by the formation of autophagosomes and autolysosomes using fluorescent and transmission electron microscopy and by expression of key mediators in the autophagic pathway. RESULTS: RSG treatment ameliorated a rebound intraocular pressure (IOP) elevation, prolonged the survival of filtering blebs, and attenuated subconjunctival fibrosis in rabbits following trabeculectomy. Pretreatment of HTFs with RSG inhibited TGF-β1-induced expression of profibrotic genes encoding specificity protein 1, connective tissue growth factor, and α smooth muscle actin. RSG augmented TGF-β1-induced autophagy in HTFs via a beclin1/VPS34-dependent mechanism. Augmentation of autophagy is associated with inhibition of TGF-β1-induced profibrotic gene expression by RSG. CONCLUSIONS: RSG treatment prevents subconjunctival fibrosis after GFS by inhibition of profibrotic gene expression through a mechanism involved in promoting autophagy in local fibroblasts. RSG represents a novel antifibrotic drug with the potential to improve the success rate of GFS.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhang F, Liu K, Cao M, et al. Rosiglitazone Treatment Prevents Postoperative Fibrosis in a Rabbit Model of Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci. 2019. PMID: 31247081. doi:10.1167/iovs.18-26526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。